Jaguar health reports voting results from january 2023 special meeting of stockholders

All proposals approved company announces 1-for-75 reverse stock split to support compliance with nasdaq listing standards shares of jaguar health common stock to begin trading on split-adjusted basis on january 23, 2023 patient enrollment expected to complete in q2 2023 for company's pivotal phase 3 ontarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy san francisco, ca / accesswire / january 20, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced the voting results of the company's special meeting of stockholders (the "special meeting") held on january 20, 2023 and announced that the company will effect a reverse stock split of its issued and outstanding voting common stock ("common stock"), at an exchange ratio of 1-for-75, on monday, january 23, 2023 (the "effective date") in order to support the company's compliance with nasdaq's listing standards. the company's common stock will begin trading on a split-adjusted basis when the market opens on the effective date and will remain listed on the nasdaq capital market under the symbol "jagx".
JAGX Ratings Summary
JAGX Quant Ranking